CMS Open Payments · Program Year 2024
U.S. Virgin Islands
U.S. Virgin Islands received $17,748.85 in pharmaceutical-industry payments to 22 physicians and 0 teaching hospitals across 106 transactions.
- $17.7K
- Total payments
- $16.8K
- To physicians
- $0.00
- To teaching hospitals
- #55
- of 59 states
In CMS Open Payments Program Year 2024, pharmaceutical and medical-device companies reported $17.7K in payments to 22 physicians and 0 teaching hospitals in U.S. Virgin Islands. That ranks U.S. Virgin Islands #55 of 59 states and territories (0.0% of the US total), averaging $763.83 per physician. Figures are company-reported under the Physician Payments Sunshine Act; a reported payment is a financial relationship, not evidence of wrongdoing.
The verdict
U.S. Virgin Islands pairs modest payment volume with an overwhelmingly physician-directed payment mix.
- #55
- of 59 states
- 0.0%
- of the national total
- 94.7%
- to physicians vs. hospitals
- 22
- physicians paid
What the Data Shows for U.S. Virgin Islands
U.S. Virgin Islands sits in the lower-volume tercile at #55 of 59 (0.0% of US dollars). The PY2024 file still records $17,748.85 across 106 transactions.
The distinctive cut versus volume is the physician share: 94.7% of dollars to 22 physicians ($763.83 each). Average transaction $167.44. Leading nature of payment: "Travel and Lodging" at $8.7K (48.9% of the state file; top-three natures 99.2%).
U.S. Virgin Islands sits in the 8th percentile (lower-volume tier). Just above: Armed Forces Pacific ($73.6K). Just below: Guam ($13.1K). For context: top-ranked California ($342.4M) is 19290.7× larger than U.S. Virgin Islands. CMS Sunshine Act framework and methodology.
Physician vs Hospital Payments
How pharmaceutical payments in U.S. Virgin Islands are distributed between physicians and teaching hospitals.
Physician Payments
$16.8K
94.7% of total · 22 recipients · $763.83 avg
Teaching Hospital Payments
$0.00
0.0% of total · 0 hospitals · $0.00 avg
Payment Breakdown by Type
U.S. Virgin Islands has 4 types of pharmaceutical payments. "Travel and Lodging" accounts for 48.9%.
Nature concentration in U.S. Virgin Islands
Top three Open Payments natures are 99.2% of state dollars; residual is every other reported nature
Payment categories in U.S. Virgin Islands
Top categories by total reported dollar volume
| Payment Type | Amount | Transactions | % of State |
|---|---|---|---|
| Travel and Lodging | $8.7K | 6 | 48.9% |
| Consulting Fee | $6.0K | 4 | 33.8% |
| Food and Beverage | $2.9K | 93 | 16.5% |
| Education | $142.58 | 3 | 0.8% |
Read with this U.S. Virgin Islands Open Payments read
Volume neighbors, physician-share peers, and the national nature catalog, not the same three guides on every state page.
- Next higher total: Armed Forces Pacific ($73.6K)
- Next lower total: Guam ($13.1K)
- Nearest physician-share mix: Minnesota (93.7% to physicians)
- Nearest physician-share mix: Armed Forces Pacific (96.8% to physicians)
- Nearest physician-share mix: Hawaii (97.3% to physicians)
- National catalog for leading nature here: Travel and Lodging (48.9% of U.S. Virgin Islands)
- State payment rankings (includes U.S. Virgin Islands at #55)
- How Open Payments natures are defined
Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. Total industry payments: $13.9B across 1,925 companies.
Read our methodology - how this data is sourced, computed, and verified.
Source: CMS Open Payments Database Industry payments to physicians and teaching hospitals · 2024
What U.S. Virgin Islands totals can and cannot tell you
The aggregate payment figure for U.S. Virgin Islands measures reportable industry–physician engagement inside this state's geographic footprint for Program Year 2024, not any one physician's or hospital's relationship with industry. CMS collects the data under the Physician Payments Sunshine Act; manufacturers must report transfers of value above the de minimis threshold. The file does not capture DTC advertising, internal R&D, wholesale drug pricing, or salary support that is not a reportable transfer of value.
Correlations between payment receipt and prescribing appear in peer-reviewed work for specific drugs and specialties, but this page's state total does not establish causation. Open the company and recipient detail pages for category and year-over-year cuts.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.